AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 212 min read$ABT

Abbott plans to spin out its nutrition business

Abbott plans to spin off its nutrition business, which has $8.5B annual sales, into a separate publicly traded company by late 2027. The move aims to focus on higher-growth markets. Abbott's Q3 revenue was $13.01B, with nutrition contributing $2.26B. The spinout is not expected to impact 2026-2027 guidance. Abbott faces ongoing litigation related to its nutrition business.

Original reporting
finance.yahoo.com
Published Oct 21, 2026, 4:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 4:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott plans to spin out its nutrition business — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ABTBullishMed
01

Why it matters

The spinout is expected to improve Abbott's margin profile and focus, while the new nutrition company will inherit both revenue streams and ongoing legal exposures.

02

Market read

A major restructuring of a large‑cap healthcare company that could reshape earnings expectations and sector dynamics.

03

What to watch

Regulatory approval timeline and the ability of the new company to secure independent financing may affect the ultimate value creation.

Relevance 7/10Novelty 8/10Timing: announced today

Background

Abbott's nutrition segment has faced litigation and a DOJ settlement, prompting a strategic decision to separate it from the core medical business.

Company-level read

Ticker impact

$ABTBullishHigh confidence
Context

Abbott announced a plan to spin out its nutrition business into a separate publicly traded company, a first‑time disclosure of a major corporate restructuring.

Expected impact

modest upside for ABT as investors price in higher margins and a clearer growth narrative

Evidence & confidence

The nutrition unit accounts for $2.26B Q3 revenue with margins below corporate average; its removal should lift earnings per share and reduce litigation risk, supporting a bullish view.

Market effects

Sector

May prompt other med‑tech firms to consider similar spinouts of low‑margin consumer segments.

Regional

U.S. healthcare and consumer health sectors could see re‑rating as focus shifts to higher‑margin medical devices and diagnostics.

Global

Limited to investors tracking large‑cap U.S. healthcare stocks; no immediate global macro effect.

Counterpoint

What could challenge this read

The spinout could create short‑term volatility and valuation uncertainty for the new nutrition entity, potentially dragging down the parent if execution stalls.

Key entities

  • Company
    Abbott Laboratories

    U.S. healthcare conglomerate planning the spinout.

  • Executive
    Robert Ford

    CEO of Abbott, quoted on the strategic rationale.

Read at source← All news

StoryAbbott to spin off Nutrition unit into independent public company by late 2027

Also covered by

4 outlets

Related articles

OCT 21
$RTXHighAI 8/10

Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm

Nasdaq Composite and Russell 2000 led a three-day market rally, with Nasdaq up 2.14% and Russell 2000 up 2.36% for the week. The Dow and S&P 500 also gained over 1.2%. Several companies reported earnings, including RTX (NYSE: RTX), Abbott (NYSE: ABT), CME Group (Nasdaq: CME), M/I Homes (NYSE: MHO), and Lockheed Martin (NYSE: LMT). RTX reported $25.0B in Q3 sales and raised its full-year outlook. Abbott posted 14.5% sales growth. CME Group saw record Q3 revenue.

prnewswire.com3 min
OCT 21
$ABTHighAI 8/10

Abbott Laboratories (ABT) Reports Q3 Results and Plans Nutrition

Abbott Laboratories (ABT) reported Q3 adjusted EPS of $1.42, with revenue up 14.5% YoY to $13.01B. Q4 EPS guidance met expectations, but full-year 2026 sales growth forecast was lowered to ~6%. The company plans to spin off its Nutrition business by the end of 2027, aiming to focus on higher-growth healthcare sectors. Medical Devices and Diagnostics saw strong growth, while Diabetes Care faced reimbursement challenges.

gurufocus.com2 min
OCT 21
$ABTMedAI 8/10

What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call

Abbott Laboratories (ABT) reported Q3 comparable sales up 7% and adjusted EPS of $1.42, in line with guidance. The company expects sales growth to accelerate post-nutrition separation and forecasts Q4 adjusted EPS of $1.62-$1.67. Abbott also provided updates on its medical device pipeline and near-term pressures in electrophysiology and diabetes care.

finance.yahoo.com3 min
OCT 21
$ABTMedAI 8/10

Abbott Laboratories Q3 2026 Earnings Call Summary

Abbott Laboratories reported Q3 2026 sales growth of 7%, driven by diagnostics and electrophysiology. The company plans to separate its nutrition business by late 2027, aiming for accelerated sales and margin growth. Q4 guidance includes a temporary headwind in the LAA market. Management expects continued growth in 2027, with new product launches. The nutrition spin-off is expected to be tax-free, with both entities maintaining strong capital positions.

finance.yahoo.com3 min
OCT 21
$ABTHighAI 8/10

Abbott Laboratories earnings analysis: questions answered and next catalysts

Abbott Laboratories (ABT) reported Q3 2026 earnings matching expectations, with revenue of $13.01B and adjusted EPS of $1.42. The stock fell 3.42% due to a guidance cut, trimming full-year sales growth to 6%. Diagnostics and nutrition sales grew, but electrophysiology and diabetes care slowed. Management plans to separate the nutrition business. Next catalysts include Libre Duo launch, payer formulary changes, and Q4 results.

investing.com2 min